Proteomics and Metabolomics Shared Resource Project Summary/Abstract The Proteomics and Metabolomics Shared Resource (PMSR) consists of a Fred Hutchinson Cancer Research Center (FHCRC)-based Proteomics/Metabolomics laboratory and a University of Washington-South Lake Union (UW-SLU) laboratory. The Proteomics section of the PMSR was formed in November 2002 with the goal of providing cost-effective high performance liquid chromatography and mass spectrometry-based proteomics services to Cancer Consortium (Consortium) members. The Proteomics resource's mission is to provide high quality service in a timely manner for small- and large-scale qualitative and quantitative proteomics analyses, protein modification characterization, and targeted proteomic analyses. These services have evolved from small-scale identification of protein complexes in model systems and identifying modifications on highly purified proteins to large-scale biomarker discovery/validation experiments in serum samples and phosphoproteomics analysis of animal organs. The PMSR received an outstanding merit assessment in 2008. In 2010, the PMSR was expanded to include metabolomics research and related resources through the joint recruitment of Daniel Raftery, Ph.D., a recognized leader in metabolomics research, to FHCRC and the University of Washington (UW). Along with the proteomics services mentioned above, the resource now provides untargeted profiling of aqueous metabolites and lipids (lipidomics), targeted profiling of metabolites from numerous metabolic pathways via mass spectrometry and nuclear magnetic resonance spectroscopy, and isotope tracer capabilities. The PMSR is also rapidly developing mass spectrometry phospholipid analysis. The resource is committed to developing and implementing new proteomics and metabolomics tools in order to uncover the molecular details that influence cancer biology and to support development of diagnostic and clinical tests. Scientific operations of the Proteomics and Metabolomics resource are divided between FHCRC and UW- medicine sites. Dr. Gafken oversees all operations at FHCRC and Dr. Raftery oversees those at UW. Drs. Gafken and Raftery meet on a monthly to coordinate activities, or more frequently if needed for specific projects. All proteomics-based projects are performed at FHCRC while metabolomics-based projects are divided between the two sites. Metabolomics projects for which established, routine assays are available are performed at FHCRC while those metabolomics projects that are non-routine and require significant development are performed at UW. As new metabolomics assays are developed and refined at the UW site, FHCRC-based staff will be trained on these protocols to make them more widely available as a service. All NMR capabilities and NMR-related projects will be conducted at UW-SLU.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015704-44S1
Application #
9842435
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Witzky, Anne; Hummels, Katherine R; Tollerson 2nd, Rodney et al. (2018) EF-P Posttranslational Modification Has Variable Impact on Polyproline Translation in Bacillus subtilis. MBio 9:
Rosenthal, Elisabeth A; Shirts, Brian H; Amendola, Laura M et al. (2018) Rare loss of function variants in candidate genes and risk of colorectal cancer. Hum Genet 137:795-806
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Correction: Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis (doi:10.1242/211573). J Cell Sci 131:

Showing the most recent 10 out of 1267 publications